Icosapent Ethyl
- Generic Name
- Icosapent Ethyl
- Brand Names
- Vascepa, Vazkepa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H34O2
- CAS Number
- 86227-47-6
- Unique Ingredient Identifier
- 6GC8A4PAYH
- Background
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on July 26, 2012.
- Indication
作为最大耐受他汀类药物治疗的辅助手段，以降低甘油三酯（TG）水平升高（≥150mg/dL）、已确定的心血管疾病或糖尿病以及2个或更多心血管疾病风险因素的成年患者需要住院治疗的心肌梗死、中风、冠状动脉血运重建和不稳定心绞痛的风险。
- Associated Conditions
- Hospitalizations, Severe Hypertriglyceridemias
- Associated Therapies
- -
Omega-3s for heart health? Exploring potential benefits and risks
Fish oil omega-3 supplements' effectiveness in heart disease prevention is uncertain, with mixed clinical trial results and potential risks. VITAL trial showed no overall CVD risk reduction but significant benefits for low fish consumers, high-risk individuals, and African Americans. REDUCE-IT trial found icosapent ethyl reduced CVD risk by 25% in high-risk patients. Research continues on optimal omega-3 forms and mechanisms, with caution advised on high-dose supplement use.
Pharma stocks: Nomura gives 'Buy' to Lupin remains 'Neutral' on others
Indian pharma giants focus on quality over quantity, with complex product filings increasing. US generics sales show slight growth, and regulatory challenges ease. Nomura recommends Lupin for its upcoming launches and stable market shares, while noting setbacks. Sun Pharma's specialty segment growth slows, and Dr Reddy's faces market share declines. Cipla and Zydus Lifesciences show growth but face inspection and competition challenges.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath